Literature DB >> 7493914

Induction of erythroid differentiation by 5-fluorouracil in K562 leukemia cells.

Y W Yang1, Y H Chang.   

Abstract

K562 cell line, established from a patient in the blast crisis of chronic myeloid leukemia, expresses high levels of c-myc and bcr/abl gene products. Exposure of K562 cells to 5-fluorouracil (5-FU) resulted in a marked benzidine-positive erythroid differentiation with concomitant reduction in cell proliferation. No change in c-myc mRNA or protein levels occurred during 96 h of drug treatment. In contrast, a biphasic change of p210bcr/abl and the abl-associated kinase activities was observed upon treatment with 5-FU. The change in p210bcr/abl expression may be mediated at the translational level, since the steady-state level and the enzymatic activity of p210bcr/abl are reduced, whereas bcr/abl mRNA levels are unaltered. The results are consistent with the existence of pleiotropic differentiation pathways in K562 cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7493914      PMCID: PMC5920591          DOI: 10.1111/j.1349-7006.1995.tb03006.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  26 in total

Review 1.  Leukemia and the disruption of normal hematopoiesis.

Authors:  C L Sawyers; C T Denny; O N Witte
Journal:  Cell       Date:  1991-01-25       Impact factor: 41.582

2.  Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

Authors:  T G Lugo; A M Pendergast; A J Muller; O N Witte
Journal:  Science       Date:  1990-03-02       Impact factor: 47.728

3.  Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.

Authors:  G Q Daley; R A Van Etten; D Baltimore
Journal:  Science       Date:  1990-02-16       Impact factor: 47.728

4.  Effect of differentiation-inducing agents on oncogene expression in a chronic myelogenous leukemia cell line.

Authors:  A Eisbruch; M Blick; M J Evinger-Hodges; M Beran; B Andersson; J U Gutterman; R Kurzrock
Journal:  Cancer       Date:  1988-09-15       Impact factor: 6.860

5.  Expression of c-myc changes during differentiation of mouse erythroleukaemia cells.

Authors:  H M Lachman; A I Skoultchi
Journal:  Nature       Date:  1984 Aug 16-22       Impact factor: 49.962

Review 6.  Systemic therapy for colorectal cancer: an overview.

Authors:  R J Mayer
Journal:  Semin Oncol       Date:  1991-10       Impact factor: 4.929

7.  A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia.

Authors:  A de Klein; A G van Kessel; G Grosveld; C R Bartram; A Hagemeijer; D Bootsma; N K Spurr; N Heisterkamp; J Groffen; J R Stephenson
Journal:  Nature       Date:  1982-12-23       Impact factor: 49.962

8.  In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome.

Authors:  J McLaughlin; E Chianese; O N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  1987-09       Impact factor: 11.205

9.  Constitutive c-myc oncogene expression blocks mouse erythroleukaemia cell differentiation but not commitment.

Authors:  J A Coppola; M D Cole
Journal:  Nature       Date:  1986 Apr 24-30       Impact factor: 49.962

10.  Studies of hematopoietic stem cells spared by 5-fluorouracil.

Authors:  G Van Zant
Journal:  J Exp Med       Date:  1984-03-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.